PR Newswire Asia's news > Health Care/Hospital

 < Previous page   |   Title only   |   Print    Next page > 
     
Alphamab Oncology Announces Anti-HER2 Biparatopic ADC JSKN003 Obtained Orphan Drug Designation from the U.S. FDA for the Treatment of GC/GEJ
SUZHOU, China , July 29, 2025 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that anti-HER2 biparatopic antibody-drug conjugate (ADC) JSKN003 has been granted Orphan Drug Designation ...
2025-07-29T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
Agilent and Nanyang Technological University's NEWRI Sign Agreement to Enhance Water Contaminant Research in Singapore
SINGAPORE , July 29, 2025 /PRNewswire/ --  Agilent Technologies Inc.  (NYSE: A) announced the recent signing of a Memorandum of Understanding (MOU) with the Nanyang Environment & Water ...
2025-07-29T    Computer/Electronics   Education   Environmental Products & Services   Health Care/Hospital 
FROM THE ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFERENCE 2025: U.S. POINTER STUDY SHOWS STRUCTURED LIFESTYLE PROGRAM TARGETING MULTIPLE RISK FACTORS IMPROVES COGNITION IN OLDER ADULTS AT RISK OF COGNITIVE DECLINE
Key Takeaways ...
2025-07-29T    Health Care/Hospital   Medical/Pharmaceuticals 
Siemens Healthineers Receives Frost & Sullivan's 2025 North America Company of the Year Award for Excellence in Advanced Visualization Applications
Recognized for delivering diagnostic innovation, workflow efficiency, and enterprise imaging leadership through advanced visualization solutions ...
2025-07-28T    Computer Software   Computer/Electronics   Health Care/Hospital   Medical Equipment 
XellSmart Completed World's First Patient Dosing in its Registrational Clinical trial for iPSC-derived Subtype-specific Neural Cell Therapy for Spinal Cord Injury
SUZHOU, China , July 28, 2025 /PRNewswire/ -- XellSmart Biopharmaceutical (Suzhou/ Shanghai ) Co., Ltd. achieved a significant milestone in its "world's first" China NMPA & US ...
2025-07-28T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
World's First Engineered Exosome for Hair Growth & Localized Fat Reduction Secure INCI Designation: ImmVira Accelerates Access to Billion-Dollar Aging-related Market
SUZHOU, China , July 28, 2025 /PRNewswire/ -- ImmVira Group ("ImmVira" or the "Company")recently announced that its engineered exosome products MVR-EX104 ("EX104", ...
2025-07-28T    Biotechnology   Cosmetics & Personal Care   Health Care/Hospital   Household/Consumer/Cosmetics 
Alamar Biosciences Showcases Pioneering Brain-Derived pTau Data at the Alzheimer's Association International Conference (AAIC)
Groundbreaking Insights into Neurodegenerative Disease Biomarkers to be Unveiled through 30+ Posters and Presentations at International Meeting ...
2025-07-28T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals   Trade show news 
Herbalgy x TEEMTONEfai Make a Groundbreaking Crossover Debut Cool Vibes to Welcome Herbalgy Trophy
A Summer Cool-Off : Exclusive Mint Gelato x Icy Touch-Cool ...
2025-07-28T    Food/Beverages   Health Care/Hospital   Retail 
Antengene Announces XPOVIO® Approved in China for the Second-Line Treatment of Multiple Myeloma, Marking the Third Approved Indication of the Drug
- This approval for XPOVIO ® in combination with bortezomib and dexamethasone (XVd) for the treatment of adult patients with multiple myeloma (MM) who have received at least one prior therapy marks ...
2025-07-28T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
Interventional Robot's RCT Research Published in JNIS, a Leading Journal in Neurointervention!
SHANGHAI , July 28, 2025 /PRNewswire/ -- The multicenter, randomized controlled trial (RCT) results of the PANVIS-A® NeuroInterventional Robotic System —led by Professor Liu Jianmin (Changhai ...
2025-07-28T    Health Care/Hospital   Medical Equipment   Medical/Pharmaceuticals 
 < Previous page    Next page >

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2025 Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.